ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. December 11, 2019
ProQR Announces Strategic Changes to the Management Team and Key New Hires Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 13, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. December 13, 2018
ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. November 21, 2019
ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. September 09, 2019
ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP) Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., Aug. August 12, 2019
ProQR Appoints John Maraganore, PhD, as Strategic Advisor to the Supervisory Board Press release … rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Based on our unique … March 07, 2022
ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital Press release … rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Based on our unique … December 30, 2021
ProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated Company, Announce Exclusive Worldwide License and Discovery Collaboration for Undisclosed Target Press release Yarrow Biotechnology, Inc., a newly formed biotechnology company backed by RTW Investments, LP, will lead development of the program ProQR May 04, 2021
European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10 Press release Access based on positive interim analysis of clinical data as well as preclinical data to date PRIME designation provides a pathway for frequent and early interactions with the EMA aimed at supporting accelerated evaluation and approval July 29, 2019
ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen Press release … rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Based on our unique … January 04, 2022